Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
4.250
+0.170 (4.17%)
Jul 28, 2026, 11:59 AM EDT - Market open
Aligos Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4.71 | 2.19 | 3.95 | 15.53 | 13.91 | 4.36 | |
Revenue Growth | 45.76% | -44.59% | -74.60% | 11.66% | 219.04% | - |
Gross Profit | 4.71 | 2.19 | 3.95 | 15.53 | 13.91 | 4.36 |
Selling, General & Admin | 22.07 | 20.72 | 22.83 | 30.62 | 26.41 | 28.53 |
Research & Development | 78.3 | 69.45 | 70.27 | 73.04 | 85.08 | 104.15 |
Total Operating Expenses | 100.38 | 90.17 | 93.1 | 103.66 | 111.49 | 132.68 |
Operating Income | -95.67 | -87.99 | -89.15 | -88.13 | -97.58 | -128.32 |
Interest Income | 3.85 | 3.92 | 4.41 | 3.41 | 1.64 | 0.13 |
Other Non-Operating Income (Expense) | 2.09 | 60.18 | -46.13 | -2.17 | - | - |
Total Non-Operating Income (Expense) | 5.94 | 64.11 | -41.73 | 1.24 | 1.64 | 0.13 |
Pretax Income | -89.73 | -23.88 | -130.88 | -86.88 | -95.94 | -128.19 |
Provision for Income Taxes | 0.59 | 0.31 | 0.33 | 0.8 | 0.11 | 0.14 |
Net Income | -90.32 | -24.19 | -131.21 | -87.68 | -96.05 | -128.33 |
Net Income to Common | -90.32 | -24.19 | -131.21 | -87.68 | -96.05 | -128.33 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 10 | 10 | 6 | 3 | 2 | 2 |
Shares Outstanding (Diluted) | 10 | 10 | 6 | 3 | 2 | 2 |
Shares Change | 50.77% | 57.79% | 144.38% | 50.10% | 7.12% | 299.03% |
EPS (Basic) | -8.69 | -2.45 | -20.94 | -34.20 | -56.25 | -80.50 |
EPS (Diluted) | -8.69 | -2.45 | -20.94 | -34.20 | -56.25 | -80.50 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -85.19 | -82.94 | -80.87 | -79.02 | -80.33 | -116.55 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -8.21 | -8.39 | -12.91 | -30.82 | -47.04 | -73.11 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -2033.39% | -4024.93% | -2259.92% | -567.50% | -701.66% | -2943.82% |
Profit Margin | -1919.68% | -1106.72% | -3326.01% | -564.62% | -690.63% | -2944.07% |
FCF Margin | -1810.52% | -3794.14% | -2050.01% | -508.83% | -577.64% | -2673.87% |
EBITDA | -94.59 | -87.06 | -88.13 | -86.57 | -95.27 | -125.3 |
EBITDA Margin | -2010.39% | -3982.39% | -2233.89% | -557.46% | -685.08% | -2874.56% |
EBIT | -95.67 | -87.99 | -89.15 | -88.13 | -97.58 | -128.32 |
EBIT Margin | -2033.39% | -4024.93% | -2259.92% | -567.50% | -701.66% | -2943.82% |
Effective Tax Rate | -0.66% | -1.31% | -0.25% | -0.92% | -0.11% | -0.11% |